Krystal Biotech (KRYS) Retained Earnings (2016 - 2026)
Krystal Biotech (KRYS) posted quarterly Retained Earnings of $1.2 billion for Q2 2026, up 7.2% year-over-year from $1.1 billion in Q2 2025, and up 2.53% on a QoQ basis from $1.2 billion in Q1 2026.
Krystal Biotech (KRYS) Retained Earnings (2016 - 2026) Analysis & Trends
Krystal Biotech has reported Retained Earnings for 11 years, with the latest figure at $1.2 billion in Q2 2026.
- Retained Earnings for Q2 2026 came in at $1.2 billion, up 7.2% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.2 billion (up 7.2% YoY), and the FY2025 annual result was $1.2 billion, up 5.95% from the prior year.
- Retained Earnings improved to $1.2 billion in Q2 2026, from $1.2 billion in the prior quarter.
- Over five years, Retained Earnings peaked at $1.2 billion in Q2 2026 and troughed at $740.5 million in Q1 2022.
- A 5-year average of $1.0 billion and a median of $1.1 billion in 2024 frame the typical range for Retained Earnings.
- The widest annual swing landed in 2022, when Retained Earnings jumped 50.02%; it then increased 4.82% in 2025.
- A 5-year view of Retained Earnings shows it stood at $803.7 million in 2022, then soared by 30.37% to $1.0 billion in 2023, then advanced by 7.58% to $1.1 billion in 2024, then gained by 5.95% to $1.2 billion in 2025, then advanced by 2.88% to $1.2 billion in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were $1.2 billion in Q2 2026, $1.2 billion in Q1 2026, and $1.2 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 1.23 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.23 Bn |
| Mar 31, 2026 | 80.10 Mn |
| Dec 31, 2025 | 24.16 Mn |
| Sep 30, 2025 | -27.24 Mn |
| Jun 30, 2025 | -106.60 Mn |
| Mar 31, 2025 | 1.13 Bn |
| Dec 31, 2024 | -190,000.00 |
| Sep 30, 2024 | 1.11 Bn |
| Jun 30, 2024 | -253.33 Mn |
| Mar 31, 2024 | -299,000.00 |
| Dec 31, 2023 | 1.05 Bn |
| Sep 30, 2023 | 1.03 Bn |
| Jun 30, 2023 | 1.01 Bn |
| Mar 31, 2023 | -326.10 Mn |
| Dec 31, 2022 | 803.72 Mn |
| Sep 30, 2022 | -1.48 Mn |
| Jun 30, 2022 | -1.55 Mn |
| Mar 31, 2022 | -190.70 Mn |
| Dec 31, 2021 | -140.78 Mn |
| Sep 30, 2021 | -118.98 Mn |